Isotretinoin: Updated prescribing guidance
The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin following a review of measures implemented in 2023. Healthcare professionals are asked to review the updated guidance to ensure safe prescribing and patient management.
Key points
- Risk minimisation measures for isotretinoin have been reviewed and updated
- Changes follow assessment of the effectiveness of 2023 measures
- All prescribers, pharmacists and other healthcare professionals should familiarise themselves with the new requirements
- Patient safety remains the priority in isotretinoin therapy
Affected medication
- Isotretinoin (all formulations and brands)
What you need to do
- Review the full MHRA guidance on the updated risk minimisation measures
- Ensure your team understands the changes before prescribing or dispensing isotretinoin
- Communicate relevant updates to patients currently on isotretinoin therapy
- Refer to the MHRA source document for complete prescribing requirements
For the full alert and detailed guidance, visit the MHRA drug safety update.